![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, March 24, 2012 5:45:46 PM
In the last decade it has become obvious that myeloid-derived suppressor cells (MDSC) play an
important role in immune suppression induced by cancer tumors. Only more recently has it
been shown by Thorpe's group that bavituximab can reduce the amount of MDSC and also
switch macrophages from M2 to M1 phenotype. See Thorpe's keynote address, "Targeting Tumor
Vasculature and Reactivating Tumor Immunity with Bavituximab", at the Barcelona antibody
conference on May 26, 2011, and last year's AACR meeting poster for abstract #3651.
Several papers have been published in the last few years which show that some chemo drugs also
reduce the amount of MDSC and can affect such a switch in macrophages.
The interesting thing is that these are drugs that are currently in clinical trials with bavituximab.
The drugs and cancers are: docetaxel and second-line NSCLC, gemcitabine and pancreatic cancer, sorafenib and HCC.
Here are three papers which support these ideas:
Docetaxel: Kodumudi et al, Clinical Cancer Research, 16(18), 4583-4594 (2010).
A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers.
http://clincancerres.aacrjournals.org/content/16/18/4583.abstract
Gemcitabine: Sinha et al, The Journal of Immunology, 179(2), 977-83, (2007).
Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.
http://www.jimmunol.org/content/179/2/977.long
Here is an interesting figure from this paper
![](http://investorshub.advfn.com/uimage/uploads/2012/3/24/hffdrCross-talk.jpg)
Sorafenib: Cao et al, Laboratory Investigation, 91, 598-608 (2011).
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.
http://www.nature.com/labinvest/journal/v91/n4/abs/labinvest2010205a.html
That these three drugs have also become the "gold standards" for the respective cancers is probably
due to their immune modulating activity, in addition to their cytotoxic effects. Now that it has been
shown that the MOA of bavituximab includes these very same immune modulating effects the hope
is that using bavi with these drugs will result in a synergy which goes well beyond the effect of each alone.
Thorpe's group have published a paper showing this in mice with pancreatic cancer:
Beck et al, International Journal of Cancer,118, 2639-2643 (2006).
Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice.
http://onlinelibrary.wiley.com/doi/10.1002/ijc.21684/full
and for docetaxel with breast cancer: Huang et al, Cancer Research, 65 (10), 4408-4416 (2005).
A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice.
Last year at the AACR meeting they presented the poster for abstract # 3643, on bavi and sorafenib in HCC,
which shows such a synergistic effect. See my post #73697, and this year's AACR meeting abstract # 5591.
The beauty of this is that these chemo drugs are indeed the "gold standards", so if using Bavi with
them increases survival, without increasing toxicity, then acceptance would seem to follow.
Recent CDMO News
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM